The most common origin of hypoprolactinemia is iatrogenic, consequent to medical therapy with the atypical antipsychotic aripiprazole or mostly with dopamine agonists, particularly cabergoline, which represents the cornerstone of treatment of hyperprolactinemia due to PRL-secreting pituitary tumours [61]. This evidence concerns the gene PRL and hyperprolactinemia.